stoxline Quote Chart Rank Option Currency Glossary
Lantheus Holdings, Inc. (LNTH)
69.53  -1.46 (-2.06%)    11-28 15:15
Open: 71.02
High: 71.75
Volume: 415,002
Pre. Close: 70.99
Low: 69.45
Market Cap: 4,762(M)
Technical analysis
2023-11-28 2:49:42 PM
Short term     
Mid term     
Targets 6-month :  83.8 1-year :  97.88
Resists First :  71.75 Second :  83.8
Pivot price 67.11
Supports First :  64.6 Second :  60.18
MAs MA(5) :  69.18 MA(20) :  66.41
MA(100) :  70.5 MA(250) :  72.51
MACD MACD :  0.8 Signal :  0.2
%K %D K(14,3) :  83.8 D(3) :  79.9
RSI RSI(14): 56.3
52-week High :  100.85 Low :  47.45
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LNTH ] has closed below upper band by 25.1%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 71.43 - 71.7 71.7 - 71.97
Low: 67.29 - 67.62 67.62 - 67.94
Close: 70.46 - 70.96 70.96 - 71.47
Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Headline News

Tue, 28 Nov 2023
A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH) - Simply Wall St

Mon, 27 Nov 2023
Add Up The Pieces: IVOO Could Be Worth $99 - Nasdaq

Fri, 17 Nov 2023
Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock - Yahoo Finance

Wed, 08 Nov 2023
Lantheus to Present at the Jefferies London Healthcare Conference - Yahoo Finance

Mon, 06 Nov 2023
Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now? - Nasdaq

Sat, 04 Nov 2023
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—Specialty & Generic
Shares Out 68 (M)
Shares Float 67 (M)
Held by Insiders 2.7 (%)
Held by Institutions 100.8 (%)
Shares Short 4,840 (K)
Shares Short P.Month 4,900 (K)
Stock Financials
EPS 1.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.19
Profit Margin 8.6 %
Operating Margin 35.1 %
Return on Assets (ttm) 8.7 %
Return on Equity (ttm) 15.5 %
Qtrly Rev. Growth 33.7 %
Gross Profit (p.s.) 8.49
Sales Per Share 17.66
EBITDA (p.s.) 3.51
Qtrly Earnings Growth 118.5 %
Operating Cash Flow 298 (M)
Levered Free Cash Flow -270 (M)
Stock Valuations
PE Ratio 46.45
PEG Ratio 0.3
Price to Book value 6.83
Price to Sales 3.94
Price to Cash Flow 15.99
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android